VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASCO 2019 | ARROW: carfilzomib dosing in frail R/R multiple myeloma patients

The ARROW study (NCT02412878) investigated the safety and efficacy of once-weekly carfilzomib dosing in frail relapsed/refractory multiple myeloma patients. Maria-Victoria Mateos, MD, PhD, of the Institute of Biomedical Research of Salamanca, Salamanca, Spain, discuses this study at the American Society of Oncology (ASCO) 2019 Annual Meeting, held in Chicago, IL.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter